Stellar Biotech Inc (SBOTF) 1.1915 $SBOTF
Stellar Biotechnologies Launches New Corporate Website
Marketwire Canada - Fri May 02, 7:01AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the launch of its new corporate website at www.stellarbiotech.com.
Stellar Biotechnologies Reports Second Quarter 2014 Financial Results and Recent Corporate Developments
Marketwire - Thu Apr 10, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has reported financial results for the second quarter and six months ended February 28, 2014, and provided operational highlights.
Stellar Biotechnologies to Host Corporate Update and Second Quarter 2014 Results Conference Call on April 10
Marketwire Canada - Fri Apr 04, 8:01AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , will host a general corporate update conference call and webcast at 1:30 PM ET (10:30 AM PT) on April 10, 2014.
Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50(R) Spotlight Event
Marketwire - Tue Apr 01, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced that the company is presenting today at the 2014 TSX Venture 50(R) Spotlight Event being held in Calgary, Canada.
Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference
Marketwire Canada - Mon Mar 03, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California.
Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
Marketwire Canada - Thu Feb 27, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein, announced today that the Company will present at the 26th Annual ROTH Capital Partners Growth Conference to be held March 9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
Stellar Biotechnologies Reports on Annual General and Special Meeting
Marketwire - Tue Feb 18, 8:06AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting" on Thursday, February 13, 2014 at which all Meeting resolutions were approved. The resolutions passed at the Meeting include the following:
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Stellar Biotechnologies Named 2014 TSX Venture 50(R) Company
Marketwire Canada - Thu Feb 13, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has been named to the 2014 TSX Venture 50(R), an exclusive ranking of the top performing companies on the TSX Venture Exchange.
Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference
Marketwire Canada - Wed Feb 12, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), describing a new method for verifying authenticity of Keyhole Limpet Hemocyanin (KLH) product.
Mindoro Welcomes Significant New Investor as Prime Resources Holdings, Inc. Acquires 13.33% of Mindoro's Shares
Marketwire - Fri Jan 17, 7:01AM CST
Mindoro Resources Ltd. (TSX VENTURE: MIO)(ASX: MDO)(FRANKFURT:WKN 906167) ("Mindoro", or "the Company" is pleased to advise that Prime Resources Holdings, Inc. ("PRHI" has acquired approximately 13.33% of Mindoro's issued and outstanding common shares through a secondary trade in the market.
Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
Marketwire - Mon Jan 06, 8:15AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida.
Stellar Biotechnologies Launches New Corporate Website
Marketwire Canada - Fri May 02, 7:01AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the launch of its new corporate website at www.stellarbiotech.com. Stellar Biotechnologies Reports Second Quarter 2014 Financial Results and Recent Corporate Developments
Marketwire - Thu Apr 10, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has reported financial results for the second quarter and six months ended February 28, 2014, and provided operational highlights. Stellar Biotechnologies to Host Corporate Update and Second Quarter 2014 Results Conference Call on April 10
Marketwire Canada - Fri Apr 04, 8:01AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , will host a general corporate update conference call and webcast at 1:30 PM ET (10:30 AM PT) on April 10, 2014. Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50(R) Spotlight Event
Marketwire - Tue Apr 01, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced that the company is presenting today at the 2014 TSX Venture 50(R) Spotlight Event being held in Calgary, Canada. Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference
Marketwire Canada - Mon Mar 03, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California. Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
Marketwire Canada - Thu Feb 27, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein, announced today that the Company will present at the 26th Annual ROTH Capital Partners Growth Conference to be held March 9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point, California. Stellar Biotechnologies Reports on Annual General and Special Meeting
Marketwire - Tue Feb 18, 8:06AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting" on Thursday, February 13, 2014 at which all Meeting resolutions were approved. The resolutions passed at the Meeting include the following: Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Stellar Biotechnologies Named 2014 TSX Venture 50(R) Company
Marketwire Canada - Thu Feb 13, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has been named to the 2014 TSX Venture 50(R), an exclusive ranking of the top performing companies on the TSX Venture Exchange. Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference
Marketwire Canada - Wed Feb 12, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), describing a new method for verifying authenticity of Keyhole Limpet Hemocyanin (KLH) product. Mindoro Welcomes Significant New Investor as Prime Resources Holdings, Inc. Acquires 13.33% of Mindoro's Shares
Marketwire - Fri Jan 17, 7:01AM CST
Mindoro Resources Ltd. (TSX VENTURE: MIO)(ASX: MDO)(FRANKFURT:WKN 906167) ("Mindoro", or "the Company"
is pleased to advise that Prime Resources Holdings, Inc. ("PRHI" has acquired approximately 13.33% of Mindoro's issued and outstanding common shares through a secondary trade in the market. Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
Marketwire - Mon Jan 06, 8:15AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida. 
